Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 6;20:85. doi: 10.1186/s12943-021-01366-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — Rigosertib improves T-cell responses to αPD-1/αCTLA-4 therapy. a Schematic of ICB non-responsive B16F10 melanoma model. b-d Survival of C57BL/6 female mice, day 11 tumor weight post treatment and tumor volume of B16F10 tumors. Mice reached end point and sacrificed when tumors in the experiment exceeded 15 mm in diameter or became perforated. The experiment was terminated when no mice survived in groups other than the RGS + ICB group. e Analysis of synergy. Interaction plot for tumor growth rate with 95% confidence interval by treatment. f Live CD45⁺ leukocytes were concatenated after downsampling to ~ 12,500 events for t-SNE analysis through flow cytometry and T-cell frequency was shown. g Tumor volume of YUMM3.3 tumors in C57BL/6 female mice. Treatment starts at day 10 post tumor cell inoculation. h Spider plots of tumor volume changes overtime for individual YUMM3.3 tumors. i IHC and j-l Flow cytometric analysis of YUMM3.3 tumors at day 17 post-treatment. Data were replicates from one experiment (n = 10 per group)